Accessibility Statement Skip Navigation
  • PRNewswire.com
  • +971 (0) 4 368 1644
  • GDPR
  • Journalists
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Products
  • General Inquiries
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +971 (0) 4 368 1644 from 8 AM - 5:30 PM GMT

    • Contact
    • Contact

      +971 (0) 4 368 1644
      from 8 AM - 5:30 PM GMT

  • Request More Information
  • Journalists
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Request More Information
  • Journalists
  • GDPR
  • Products
  • Request More Information
  • Journalists
  • GDPR

Maypharm Launches a New Professional set HAIRNA for Hair Loss Solution
  • USA - español
  • Россия - Pусский
  • USA - English
  • USA - Deutsch
  • USA - Français


News provided by

Maypharm

24 Dec, 2021, 10:09 GMT

Share this article

Share toX

Share this article

Share toX

SEOUL, South Korea and NEW YORK, Dec. 24, 2021 /PRNewswire/ -- Maypharm is known as a manufacturer of recently successfully launched Metox botulinum toxin with a 2nd generation technological advantage and meNnus PLA filler for collagen regeneration, now is focusing on a new professional set HAIRNA for Hair Loss Solution.

Continue Reading
HAIRNA Scalp Care Solution Line
HAIRNA Scalp Care Solution Line
HAIRNA in New York
HAIRNA in New York

New Hair Product Line consists of 5 products, a main one HAIRNA EXOSOME AMPOULE (5ml x 5 vials) with exosomes, effective in hair loss treatment; HAIRNA HAIR FILL (2.5ml), essential for hair loss prevention & normalization and additional trio of supportive HAIRNA products, which are HAIRNA SHAMPOO (300ml), HAIRNA TREATMENT (200ml) and HAIRNA TONER (150ml) to help with scalp care, hair loss issue and damaged hair cure.  

All HAIRNA products were reported to the KFDA and recognized for their stability without any irritation during all the clinical trials. Particularly, HAIRNA EXOSOME BOOSTER AMPOULE was additionally tested to see how it improved the scalp skin, elasticity, and hair loss, and the results were satisfying.

It contains 37,000 ppm of exosome, a key ingredient to relieve hair loss symptoms, and is surprisingly effective in treating alopecia areata.

It is a product that both men and women who experience hereditary and stress-related hair loss can use directly by penetrating the scalp using an MTS needle, created especially for HAIRNA Ampoules, rather than just topical application. The exosome ingredient itself is highly effective in hair loss since the process of absorption starts right from the scalp.

HAIRNA HAIR FILL with copper, panthenol and vitamin B complex works as an antioxidant for hair by normalization hair growth cycle and prevents hair loss; prevents oxidative damage to hair follicle cells by suppression of free radicals; supplies moisturization for elasticity and shining effect.

HAIR FILL benefit is found in synergy of exosome, growth factors and active ingredients which in total strengthen scalp barrier and prevent hair loss. After balancing the unhealthy scalp, hair fill helps improving the overall scalp condition and maintaining effect for a long time.

HAIRNA SHAMPOO, TREATMENT, and TONER contain main ingredients that prevent hair loss such as L-menthol, Dexpanthenol, and Salicylic Acid, which are effective in cooling scalp heat, removing sebum and dead skin cells, moisturizing, and relieving hair loss symptoms.

Maypharm has announced HAIRNA on The Times Square Spectacular digital billboard in New York in December, 2021.

Maypharm is well recognized as a wholesale distributor and manufacturer around the world in Central America, Middle East, South and South-Eastern Asian countries, Europe, particularly, in China, UK, Russia, USA, Mexican market.

"While we are becoming well known as a manufacturer of Metox, we thoroughly concentrate on taking a global position on HAIRNA now. HAIRNA Full Line is available on various global online platforms, including Amazon, Shopee, Q10, Lazada.  

Visit a website for a detailed information: http://www.maypharm.co.kr.

Contact: [email protected]

Photo - https://mma.prnewswire.com/media/1716186/1st_photo_Maypharm.jpg

Photo - https://mma.prnewswire.com/media/1716187/2nd_photo_TDP.jpg  

Related Links

http://may-pharm.com/

Modal title

Also from this source

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world's first recombinant human collagen filler, marking a significant breakthrough in skin...

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

Maypharm Co., Ltd., a leading innovator in medical and dermo-cosmetic products, proudly introduces the global launch of Hyalmass Aqua-Exosome, a...

المزيد من الإصدارات من هذا المصدر

Explore

Cosmetics and Personal Care

Cosmetics and Personal Care

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

New Products & Services

New Products & Services

المزيد من البيانات الصحفية في مواضيع ذات صلة

Contact PR Newswire

  • +971 (0) 4 368 1644
    from 8 AM - 5:30 PM GMT

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+971 (0) 4 368 1644
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.